**GRIFOLS** SCIENTIFIC AWARDS **GATRA** Grifols Antithrombin Research Awards

**GRIFOLS** 

# **GATRA**

### Grifols Antithrombin Research Awards

#### THE GATRA PROGRAM

The Grifols Antithrombin Research
Awards (GATRA) program's objective is
to identify and support research
projects on current and new uses of
antithrombin as a therapeutic product,
thereby helping to improve standards
of care and quality of life for patients.
Further goals are to establish new and
long-lasting cooperation with participating
scientists and clinicians, strengthen and
expand the existing network between
researchers and the company, and foster
relationships with key opinion leaders in
different fields.

# ABOUT THE GATRA PROGRAM

Grifols is a global biotherapeutic and biotechnology company that discovers, develops, and produces treatments and services for patients with antithrombin deficiency. Proposals may include, but are not limited to: efficacy, mechanism of action, safety and tolerability, quality of life, and pharmacoeconomics.

The GATRA program offers 1 award of €50,000 to the applicant whose proposal best matches the program objectives, according to assessment by an independent review committee.

The GATRA program aims to:

- Develop novel concepts in antithrombin research
- Encourage discovery of beneficial antithrombin applications
- Further investigate mechanisms of action or clinical effects in different indications

#### **WHO CAN APPLY**

Scientists or clinicians with an innovative idea to gain more insight into the uses of antithrombin. Applications are encouraged from both individuals and teams who may be undertaking research at hospitals, universities, or independent institutions.

Applicants to the GATRA program must:

- Present a focused project with goals that can be achieved within 12 months
- Be employed or supported by an institution

#### **REVIEW BOARD**

#### Marcel Levi (Chair)

Chairman of the
Netherlands Organization for
Scientific Research (NWO)
Professor of Medicine,
University College London, UK
Professor of Medicine, University of
Amsterdam, The Netherland

#### **Javier Corral**

Professor of Internal Medicine Department of Internal Medicine University of Murcia Centro Regional de Hemodonación IMIB-Arrixaca Murcia, Spain

#### **Wulf Dietrich**

Professor of Anesthesiology Departments of Anesthesiology and Transfusion Medicine Institute for Research in Cardiac Anesthesia Munich, Germany

#### Satoshi Gando

Advisor and Director
Acute and Critical Care Center
Department of Acute and Critical
Care Medicine
Sapporo Higashi Tokushukai Hospital
Sapporo, Japan

#### Jerrold H. Levy

Professor of Anesthesiology Associate Professor of Surgery Codirector of Cardiothoracic ICU Department of Anesthesiology of Cardiac Division Duke University School of Medicine Durham, NC, USA

#### George M. Rodgers III

Professor of Medicine and Pathology University of Utah Health Sciences Center Director of Coagulation Laboratory ARUP Laboratories Salt Lake City, UT, USA

#### Francisco M. Mota, PharmD, MSc

(non-voting Executive Secretary)
Ass. Director Global Med. Affairs Biopharma
Intensive Care
Grifols S.A
Sant Cugat del Vallés (Barcelona), Spain

### EVALUATIONS AND SELECTION OF RESEARCH PROPOSALS

Applications are evaluated based on merit, innovation, impact, and research environment/qualification of the applicant. A review board of external experts in antithrombin assess and rank the grant applications.

## TIMELINES FOR THE GATRA PROGRAM

Letter of intent submission: **Every year** from **November 1 to May 31** 

Awardee announcement: September

Additional information on the grant program, detailed timelines, the constitution of the review board and the application process can be found on our website: www.grifols.com or www.grifolsscientificawards.com



### GRIFOLS SCIENTIFIC AWARDS













